attributable to CLA consumption, the safety of CLA has not yet been examined in Japanese subjects.
Riserus et al. 17) showed in a short-term clinical study that a preparation containing a high concentration of the 10t, 12c-CLA isomer at 3.4 g/day dose increased insulin resistance in men with metabolic syndrome, although the CLA mixture (9c, 11t-and 10t, 12c-CLA) group showed no effect on insulin resistance in comparison with a placebo group. Another study from the same laboratory reported an increase in the urinary excretion of F 2 -isoprostanes, a possible indicator of lipid peroxidation, and this finding was consistent whether CLA supplementation was with purified 10t, 12c-isomer or a mixture of the CLA isomers 18) . To investigate the short-term safety of dietary CLA isomer mixture (as a 50:50 mixture of 9c, 11t-and 10t, 12c-isomers), we conducted a 3-month randomized, double-blind, placebo-controlled trial in overweight Japanese volunteers. In this trial, we administered relatively large amounts of CLA-triaclyglycerol, 5.4 and 10.8 g/day as compared to the dosage so far experienced in previous human studies, up to 7.5 g/day as CLA-triaclyglycerol 19) . Thus, the dosage of 10.8 g/day as CLA-triaclyglycerol at least corresponds to approximately half as much that of the reported studies.
EXPERIMENTAL

1 2.1.1 Subjects
Healthy male volunteers (n=60) aged 25-60 years with a body mass index (BMI) of 25-35, waist circumference of above 85 cm, and a visceral fat area of more than 100 cm 2 were recruited by Medical Corporation Shinanokai, Shinanozaka Clinic, Tokyo, Japan. Those subjects who were receiving drug therapy, consuming a special diet, or taking dietary supplements for weight loss were excluded from the study. Subjects with endocrine obesity, inheritable obesity, hypothalamic obesity, or drug-related obesity also were excluded. The study was carried out in accordance with the Helsinki Declaration of 1995 (as revised in 2000) and was approved by the Ethics Committee of Shinanozaka Clinic. The procedures were explained in detail to all the volunteers in advance, and all gave their signed informed consent before participating in the study.
Study design
This was a randomized, double-blind, placebo-controlled trial stratified only by Shinanozaka Clinic Co., Ltd. The subjects were randomly assigned to groups ingesting 10.8 g high-linoleic safflower oil (placebo, n=20), 10.8 g of an oil mixture (a 50:50 mixture of high-linoleic safflower oil and CLA-triacylglycerol, 3.4 g as CLA isomers, n=20), or 10.8 g CLA-triacylglycerol (6.8 g as CLA isomers, n=20). CLA-triacylglycerol was the product of The Nisshin OilliO Group, Japan, and contained 63% CLA, as an equal proportion of the 9c, 11t-and 10t,12c-isomers. The daily doses was divided into three doses taken at breakfast, lunch and dinner as 12 soft gel capsules, all identical in taste and appearance. The randomization list was kept confidential and was opened only after closure of the database. Because the purpose of the study was to examine the effects of CLA in overweight subjects consuming an ad libitum diet, neither restrictions in lifestyle nor caloric intake were implemented. However, the subjects were given an aerobic exercise burden of 3,000 walking steps per day.
2.2.1 Clinical assessment
Characteristics (including smoking and drinking habits) and demographic data were recorded when the subjects entered the study (at week 0). Weight, BMI, waist circumference, vital signs, and adverse events were recorded at 0, 6, and 12 weeks, and serious adverse events were monitored continuously throughout the study. Body composition was analyzed at 0, 6, and 12 weeks. Overnight-fasted blood samples were obtained from the subjects between 0930 and 1130 h at 0, 6, and 12 weeks, and analyzed in accredited laboratories for white blood cell count (WBC), red blood cell count (RBC), mean corpuscular hemoglobin (MCH), hematocrit (HT), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), platelet count, total protein, glucose, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), g -glutamyltranspeptidase (g -GTP), total cholesterol, triglyceride, uric acid, blood urea nitrogen, creatinine, LDL and HDL cholesterol, free fatty acid, plasminogen activator inhibitor-1 (PAI-1), leptin, and insulin. Compliance was measured at 6 and 12 weeks by comparing the number of returned capsules with the number of capsules delivered. A subject was considered compliant when he took 90% of the supplement provided.
Measurement of hepatorenal contrast by echography
The subjects underwent abdominal echography at Daido Hospital (Tokyo, Japan). Hepatorenal contrasts were determined by an abdominal ultrasonic diagnostic method.
Statistical analysis
Results are shown as means SD. Differences in the values of anthropometric measurements, body composition, fasting blood profiles, and other parameters were compared by repeated-measures analysis of variance (ANOVA). Interaction of diet group x feeding period was included in the model as a fixed effect. When significant differences were observed, comparison of means was carried out using Student's t test to examine the difference in treatment effects between the groups. Data were also tested to compare the relationships between the two periods of dietary treatment (values at 12 weeks against those at 0 week) by using one-way ANOVA. If significant differences were detected, Dunnett's procedure for multiple compar-isons was performed for evaluation of the differences among the three regulations. All analyses were performed using SPSS for WINDOWS (version 10.0J; SPSS Japan, Inc., Tokyo, Japan). Statistical significance was set at P < 0.05.
RESULTS
1
All of the 60 subjects (100%) completed the study. Compliance was 99.96% in the placebo group, 99.98% in the low CLA group, and 99.72% in the high CLA group. There were no significant differences in demographic variables when subjects included in the per-protocol analyses were examined ( ).
2
show the changes in the 24 blood parameters measured at the baseline, and at 6 and 12 weeks. There were no significant between-or within-group differences at 12 weeks for the following clinical chemistry variables: WBC, RBC, HT, MCH, platelet count, total protein, total bilirubin, g -GTP, total cholesterol, triglyceride, uric acid, blood urea nitrogen, PAI-1, and leptin. There were no significant differences in MCV, MCHC, glucose, AST, creatinine, LDL-cholesterol, HDL-cholesterol, free fatty acid, or insulin between the groups, but ALT and insulin differed significantly among the groups at 12 weeks.
MCV values were significantly higher than at the baseline, while MCHC values were significantly lower than at the baseline in all groups at 12 weeks ( ). Serum AST activity did not differ significantly among the groups at 12 weeks, but in the high CLA group it was slightly increased in comparison with baseline values. In the high CLA group serum ALT activity was significantly increased at 12 weeks and the difference between the placebo group became significant ( ). LDL-cholesterol concentration was lowered from the baseline value in all groups at 12 weeks, particularly in the placebo group, and it was significantly lower than at the baseline in this group. HDL-cholesterol concentration at 12 weeks was lower in the high CLA group than at the baseline. The concentration of free fatty acid of the placebo group at 12 weeks was significantly higher than at the baseline. Fasting blood glucose concentration in the two CLA groups was slightly higher than that at the baseline, but there was no difference among the groups at all stages ( ). The concentration of serum creatinine was significantly reduced in the placebo and the both CLA group at 12 weeks compared with that at the baseline ( ). Insulin concentration was higher in the high CLA group at 12 weeks than in the placebo group ( ). Again, there were no group-dependent differences in these parameters at all time intervals.
Several subjects in each group showed aberrant values for the following clinical chemistry variables such as total protein, glucose, triglyceride, AST, ALT, and g -GTP. Therefore, following the advice of a medical doctor, statistical analysis was done on the population of apparently healthy volunteers who had normal blood parameters at the baseline (placebo, n=8; low CLA, n=10; and high CLA, n=7). In this analysis ( ), there were no significant betweengroup differences at 12 weeks for any of the clinical variables except g -GTP. AST and ALT activities did not differ significantly among the three groups at 12 weeks. g -GTP activity at 12 week in the high CLA group remained within 519 J. Oleo Sci. 56, (10) 517-525 (2007) the normal range, although it was significantly higher than in the placebo group, the low CLA group being remained unchanged ( ).
3
The vital signs measured are listed in . Blood pressure and heart rate did not differ significantly among the 3 groups at 12 weeks. Systolic blood pressure (SBP) in the placebo group was significantly lower at 12 weeks than at the baseline. Diastolic blood pressure (DBP) in the high CLA group was significantly lower at 12 weeks than at the baseline. In two CLA groups, heart rate increased significantly from the baseline up to 12 weeks, but the betweengroup difference was not observed.
4
Adverse events were reported by 30% of the placebo group, 60% of the low CLA group, and 70% of the high CLA group (data not shown). All adverse events were mild to moderate, and included adenoiditis, diarrhea, cough, feeling of worthlessness, headache, fever, nasal inflammation, and abdominal distention. Most adverse events disap-
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peared spontaneously or were in remission after a few days.
5
shows the changes in hepatorenal contrast during the study. This parameter did not differ among three groups at 12 weeks.
6
There were no differences among three groups in daily caloric intake or daily walking steps during 12 weeks of trial ( ).
DISCUSSION
Several studies evaluating the safety and efficacy of CLA in humans have been published in America and Europe 12-17, 19, 20) . However, no reports are available regarding the safety of CLA in Japanese, and this is the first clinical study documenting the safety of dietary CLA in Japanese consuming an ad libitum diet without specific lifestyle restrictions.Dosage of 10.8 g CLA-triacylglycerol (6.8 g as CLA)/day was the largest amount so far experienced.
Previous animal studies on CLA have shown promising results with regard to safety. A toxicological study of dietary CLA in rats showed no histomorphological or hematological changes [21] [22] [23] . In contrast, dietary CLA leads to lipid accumulation and enlargement of the liver in mice, as a result of increased fatty acid mobilization from the adipose tissue [24] [25] [26] . This has not been confirmed in other animal species 5, 27) . In the present study, there was a slight increase in the level of liver enzymes (serum AST and ALT activities) in the high CLA group at 12 weeks. However, these changes were small, within the normal range, and were mild to moderate. Furthermore, statistical analysis of the population of apparently healthy volunteers who had normal blood parameters at the baseline revealed that serum AST
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J. Oleo Sci. 56, (10) 517-525 (2007) and ALT activities did not differ significantly among three groups at 12 weeks, and hepatorenal contrast also remained unchanged in all groups during the experiment. The results obtained to date from clinical trials indicate that the use of CLA does not impair liver function in overweight male humans whose blood parameters are within the normal range. Previous short-and long-term clinical studies at the dietary levels of 3.4 6.0 g/day of CLA have shown no significant changes in serum AST and ALT activities in humans 19, 20, 28) . CLA has been found to lower the plasma concentrations of total and LDL cholesterol, and triglyceride in hamsters 29) and rabbits 30) , and reduce arterial plaque in rabbits 4) . In contrast, previous short-term clinical studies in
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J. Oleo Sci. 56, (10) 517-525 (2007) 13, 17) , a reduction of VLDL without any effect on HDL or LDL 31) , and no effects on cholesterol parameters 20) . In the present study, no significant changes in blood lipid parameters were observed among three groups. Furthermore, no changes in the blood sugar levels were observed among the groups, in accordance with previous human studies 15, 19, 20) . More conformable studies are, however, required to establish the effect of CLA on blood sugar concentrations in Japanese diabetics.
The occurrence of adverse events tended to be higher in the CLA groups (3.4 and 6.8 g/day as CLA) than in the placebo group during the present study, but all adverse events were mild to moderate. In a previous human study, the occurrence of adverse events in the CLA group (3.4 g/d) was mainly of gastrointestinal origin, and the frequency of adverse events was similar among the CLA and placebo groups 20) . In addition, Gauiller et al. 16) showed that in humans 3.4 g/day of CLA for 24 months was well tolerated.
524
Safety of Dietary Conjugated Linoleic Acid
Long-term clinical studies to characterize adverse events with CLA over consumption in overweight and obese Japanese will be necessary.
CONCLUSION
In conclusion, the present results showed that a dose of 3.4 g of CLA daily for 12 weeks was well tolerated in the Japanese overweight male population. In particular, overweight volunteers who had normal blood parameters at the baseline showed no significant clinical changes in blood parameters even when 6.8 g of CLA was ingested daily for 12 weeks. The subjects reported no negative influence of the treatment on their daily life, and neither acute toxic effects nor serious adverse effects were obser ved. Although the present study confirmed the safety of relatively high levels of dietary CLA in overweight Japanese males, additional studies on human subjects with blood parameters above normal ranges are necessary in order to unequivocally confirm the safety of CLA. Of course, long term feeding studies are warranted to verify not only the safety but the beneficial effect of CLA in healthy Japanese.
